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Under FK506-based immunosuppression, 16 cadav-
eric small bowel transplantations were performed in 
15 recipients with (n==5) or without (n==11) the large 
bowel. Twelve (80%) patients are alive after 1.5 to 19 
months, 11 bearing their grafts, of which 4 include 
colon. The actuarial one-year patient and graft surviv-
als are 87.5% and 65.9%, respectively. Five grafts were 
lost to acute (n==4) or chronic (n=l) rejection, and 3 of 
these patients subsequently died after 376, 440, and 
776 days total survival. Six recipients developed se-
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vere CMV infection that was strongly associated with 
seronegative status preoperatively and receipt of 
grafts from CMV positive donors; 3 died, and the other 
3 required prolonged hospitalization. Currently, 9 pa-
tients are free from TPN 1-18 months postoperatively, 
2 require partial TPN, and one has returned to TPN 
after graft removal. The results show the feasibility of 
small bowel transplantation but emphasize the diffi-
culty of managing these recipients not only early but 
long after their operation. 
Until recently, patients with irreversible intestinal failure 
had only the socially restrictive option of parenteral nutri-
tion, which is beset by annoying as well as life-threatening 
complications. Past experience with the potential alternative 
of isolated intestinal transplantation was not encouraging, 
because of the inability to control rejection, graft-versus-host 
disease or both (1). 
Two years ago, we reported on the first five recipients of the 
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small bowel treated with the new immunosuppressive agent, 
FK506; 4 of the intestines were in combination with the liver 
and one was alone (2). We describe here our experience with 
16 isolated intestinal transplantations in 15 patients. In sev-
eral cases, part of the colon also was included. 
MATERIALS AND METHODS 
The recipients. Five recipients were children and 10 were adults 
with a mean age of 5.1::'::4.4 years and 36.5::'::11.4 years, respectively. 
Indication for isolated intestinal transplantation was short-bowel 
syndrome in 13 patients and uncorrectable intestinal disease in 2. All 
of the recipients had been managed by total parenteral nutrition 
(TPN*) from 1 to 132 months preoperatively and had experienced 
more than one episode of TPN-related complications. Bacterial 
and/or fungal sepsis and multiple line replacements were seen in all 
but one patient (case 5). Eight had major vessel thrombosis that had 
already made venous access extremely difficult. 
Abnormal histopathology of the liver was found in all 10 recipients 
from whom a biopsy was available, consisting of mild steatosis (n=3) 
or mild portal fibrosis (n = 7). Five patients had been hospitalized and 
the remaining 10 were home-bound. These and other features of the 
recipients are summarized in Table 1. 
Donor operation. The 16 cadaveric donors had the same ABO blood 
type as the recipients and were slightly larger (n=5), similar (n=8), 
or smaller (n=3) in size. All lymphocytotoxic crossmatches were 
negative, and HLA matching was universally poor. Selective bacte-
rial decontamination of the donor was started immediately after the 
donor was accepted, as described before (3,4). The grafts for patient 
1 through patient 9 consisted of the entire small intestine except for 
short segments distal to the ligament of Treitz and proximal to the 
ileocecal valve (Fig. 1A). Because these patients tended to have high 
postoperative stomal output and diarrhea, the ascending colon, with 
or without the transverse colon, was included with the small bowel in 
patients 10, 12, 13, 14, and 15 to slow intestinal transit and facilitate 
water absorption (Fig. IB). All grafts except one were flushed with 1 
L University of Wisconsin solution via the abdominal aorta, and 
preserved for a mean duration of 6.5::'::2.0 hr (ranging from 2.8 to 9.8 
hr). The exception was the first graft for patient 1, which was excised 
and simply immersed in an ice bath for 10.5 hr until transplantation. 
Luminal flushing was performed only with grafts that consisted of 
both small bowel and colon. Depletion of immunocytes was not at-
tempted in any of the grafts. 
Recipient operation. The technique for isolated intestinal trans-
plantation was essentially the same as described before (5) but with 
modifications for venous reconstruction and restoration of gastroin-
testinal tract continuity. Arterial reconstruction was performed ex-
clusively by end-to-side anastomosis of the graft superior mesenteric 
artery to the recipient infrarenal abdominal aorta. The portal vein at 
the hepatic hilum was chosen for venous reconstruction by mesen-
teric piggyback method in most of the cases (9/16) (6), but the distal 
end of the recipient superior mesenteric vein (4/16), or its confluence 
with the splenic vein (2116), was also selected if feasible. Mesocaval 
anastomosis was needed on only one occasion at the time of retrans-
plantation. 
In reestablishing GI tract continuity, 4 different types of enteros-
tomies were used for decompression and monitoring of the trans-
plant. Initially, both ends of the graft were exteriorized by the chim-
ney method (the first graft of patient 1, Fig_ 2A). For the second graft 
of patient 1, patients O~9I and patient 11, the proximal enterostomy 
was eliminated and replaced by a tube jejunostomy (Fig. 2B). In 
patients 10 and 12-14, a distal enterostomy was made with the 
transverse colon (Fig. 2C). Patient 15 had a distal ileal loop exteri-
orized by the Bishop-Koop method (Fig. 20). A tube jejunostomy was 
added for intestinal decompression and enteral feeding in all recipi-
ents except after the first transplantation in patient 1. Cholecystec-
tomy always was performed. 
* Abbreviation: TPN, total parenteral nutrition. 
Immunosuppression. FK506, steroids, and prostaglandin El (Pros-
tin) (Fig. 3) were used for postoperative immunosuppression, as is 
routine at our center for liver recipients (7). Immediately after graft 
reperfusion, FK506 at 0.1 to 0.15 mglkg/day was given intravenously, 
and then switched to oral FK506, 0.3 mg/kg/day, or usually less, 
when the recipients became tolerant to enteral feedings. To ensure 
enteric absorption, oral and i.v. doses of FK506 were allowed to 
overlap for several days with gradual weaning of the i.v. route. 
FK506 dose was adjusted to maintain trough plasma levels of 2-3 
ng/ml for the first month, 1-2 ng/ml until the third month, and 1 
ng/ml thereafter. These target levels are higher than for liver trans-
plantation. The FK506 dose was lowered if toxic side effects ap-
peared. Methylprednisolone 1 g in adults or hydrocortisone in chil-
dren was given intravenously in the operating room, and followed by 
rapid tapering of prednisone over 5 days after transplantation. Main-
tenance steroids were given thereafter or stopped when possible. 
Prostaglandin El was started at 0.2 Jlglkglhr soon after the graft was 
revascularized, gradually increased to 0.6 to 0.8 Jlglkglhr if the re-
cipient was stable, and continued until intravenous FK506 was 
stopped. 
Graft rejection was monitored by a combination of clinical find-
ings, endoscopic observation, and histopathologic examination of en-
doscope-guided mucosal biopsies. The treatment of graft rejection, 
based upon clinical, endoscopic, and mucosal biopsy findings, has 
been described elsewhere (5, 8). 
Nutritional management. Methods for nutritional management 
after intestinal transplantation have been described elsewhere (9). 
In brief, total parenteral nutrition was continued postoperatively. 
After confirming the integrity of gastrointestinal reconstruction by 
an upper GI series (usually at T~1M postoperative days), enteral 
feeding with an isoosmolar elemental diet (Peptamen) containing 
peptides and a small amount of long-chain triglycerides was begun 
via a jejunostomy tube. Enteral feedings and oral intake were gradu-
ally increased with a reciprocal decrease in parenteral nutrition. 
Prophylaxis of infection. Selective decontamination of the GI tract 
was continued for 4-6 weeks postoperatively and supplemented with 
Lv. ampicillin and cefotaxin for the first 5 days. Frequent cultures of 
the blood, stool, wound, urine, sputum, and ostomy discharge were 
obtained to monitor changes in flora and to detect evidence suggest-
ing translocation. Ganciclovir was continued for 3 to 6 months for 
prophylaxis of cytomegalovirus infection. If severe CMV infection 
occurred, foscarnet or CMV immunoglobulin was added to the gan-
ciclovir treatment. 
Assessment of graft function. Body weight, volume of stomal out-
put, and frequency and nature of the stool were common indices used 
to evaluate intestinal function. D-xylose absorption test and 72-hr 
fecal fat secretion were also studied periodically. 
RESULTS 
Postoperative course. Postoperative recovery was unevent-
ful for most of the recipients, with a median ICD stay of 6 
days (4 to 72 days, Table 1). The postoperative course of two 
adult recipients was complicated by bouts of rejection, sepsis, 
and renal failure. Patient 1 had repeated episodes of rejection 
following drug noncompliance. Patient 12 suffered from a 
poor pretransplant general condition due to his 25-year his-
tory ofCrohn's disease. Enteral feeding was started a median 
of 9 days postoperatively (range 3 to 17), and TPN was dis-
continued at a median of 30.5 days (range 18 to 300) with one 
exception. Patients were discharged after 4 to 28 weeks, as 
shown in Table 1 for each case. Mter discharge, the patients 
with a >1-month follow-up were readmitted a median of 3 
times for a median stay of 15 days. High stomal output and 
diarrhea resulting in dehydration were the leading indica-
tions for readmission, but CMV infection and rejection were 
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TABLE 1. Clinical summary of the recipients 
A. 
TPN Transplantation 
Pt. Age Sex Cause of intestinal Remaining Duration Liver (yr) failure intestine T.hil Date Graft (months) biopsy 
1 31 M Gun-shot wound Tca to rectum 6 1.1 Steatosis 5/2/90 Small bowel 
17 3/16/92 Small bowel 
2 2.5 F Microvillus Whole intestine 29 0.4 Fibrosis 10/31/91 Small bowel 
inclusion disease 
3 1.3 M Intestinal atresia TC to rectum 15 0.4 12125/91 Small bowel 
4 50 F Crohn's disease Jejunum (20 cm), 120 1 12/28/91 Small bowel 
rectum 
5 34 F Desmoid tumor Whole intestine 1 1.1 2/3/92 Small bowel 
6 38 M Crohn's disease Jejunum (10 cm), 120 1.8 3/4/92 Small bowel 
TC to rectum 
7 10.2 F Pseudo-obstruction Jejunum (20 em), 132 0.6 Fibrosis 3/6/92 Small bowel 
TC to rectum 
8 22 F Crohn's disease Jejunum (48 em), 36 0.9 Steatosis 3/12/92 Small bowel 
no colon or rectum 
9 20 F Traffic accident Jejunum (20 em), 24 1.6 6/7/92 Small bowel 
DC to rectum 
10 37 F Familial polyposis Jejunum (60 em), 32 2.8 Fibrosis 11127/92 Small bowel, 
rectum colon 
11 39 M Crohn's disease Jejunum (30 em), 80 0.7 Fibrosis 2/15/93 Small bowel 
TC to rectum 
12 35 M Crohn's disease Jejunum (15 em), 17 0.8 Steatosis 2/21/93 Small bowel, 
no colon or rectum colon 
13 58 F Colon cancer and multiple Jejunum (50 em), 17 0.7 Fibrosis 3/3/93 Small bowel, 
intestinal resections no colon or rectum colon 
14 1.7 M Gastroschisis Jejunum (15 cm), 20 0.5 Fibrosis 3/18/93 Small bowel, 
TC to rectum colon 
15 9.6 M Volvulus Jejunum (15 em), 115 0.5 Fibrosis 3/28/93 Small bowel, 
TC to rectum colon 
B. 
Hospital stay Survival (days)b Current status 
ICU Discharge 
(days) (weeks) Patient Graft TPN 
14 28 776 668 
71 
7 11 >567 >567 Free 
5 7 >512 >512 Free 
7 11 >509 >509 Free 
5 15 440 239 
6 15 376 366 
11 14 >440 >440 Partial 
4 8 >434 >434 Free 
5 5 >347 >347 Free 
7 7 >174 >174 Free 
9 9 >94 >94 Free 
72 >88 >88 Partial 
6 6 >78 >78 Free 
2 6 >63 27 
6 4 >53 >53 Free 
a TC: transverse colon; DC: descending colon. 
b As of 5/20/93. 
also prevalent indications. Patients were in the hospital a 
median of 32% of the time after their transplant admission. 
Survival. The 5 pediatric recipients are alive at home after 
53 to 567 days, and 7 of the 10 adult patients are alive after 
78 to 499 days. Three ofthe surviving 7 adult patients are at 
home while 4 are currently hospitalized for the treatment of 
CMV infection (n=3) or fungal sinusitis (n=I). Thus patient 
Comment 
Location 
Retransplanted at 684 days, kidney 
transplanted at 626 days, died of sepsis 
Home Severe cholestasis for 3 months 
Home 
Hospital CMV enteritis 
Demyelination of the brain, graft removed 
at 239 days, died of pulmonary embolism 
CMV hepatitis and enteritis, graft removed 
at 366 days, died of sepsis 
Home Gastrojejunostomy at 335 days 
Home 
Hospital CMV enteritis and retinitis 
Hospital Fungal sinusitis, CMV enteritis 
Home SMA reposition at 17 days 
Hospital CMV enteritis, pneumonitis 
Home 
Home Respiratory syncitial virus, 
graft removed at 27 days 
Home 
survival is 12115 (80%). By a life-table analysis using the 
Kaplan-Mayer method, actuarial patient survival rates at 6, 
12, and 18 months are 100%, 87.5%, and 70%, respectively 
(Fig. 4). 
Causes of graft loss and mortality. The grafts were removed 
before the deaths of the 3 adult recipients (patients 1, 5, and 
6), and in patient 1 the mortality followed subsequent re-
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FIGURE 1. Grafts for intestinal transplantation. (A) Entire small bowel except for short segments at each end on a vascular pedicle of the 
superior mesenteric artery and vein, (B) Small bowel plus ascending colon with or without the transverse colon. 
transplantation. A pediatric patient (patient 14) who under-
went graft removal at 27 days is alive after returning to TPN. 
Thus, graft survival is 11/16 (68.8%). Actuarial graft surviv-
als at 6, 12, and 18 months are 86.5%, 65.9%, and 65.9% 
respectively (Fig. 4). 
The 5 graft losses were from refractory rejection. Patient 1, 
who had a stormy course during the immediate postoperative 
period, lost his graft at 668 days from chronic rejection after 
several episodes of drug noncompliance. A second graft was 
lost to acute rejection 71 days later and he died of sepsis 22 
days after its removal, for a total survival of 776 days. The 
graft of patient 5 was removed 239 days after transplantation 
because of acute rejection that followed withdrawal of immu-
nosuppression because of a neurologic syndrome caused by 
demyelination of the white matter of the brain. She was 
discharged from the hospital on TPN but died 201 days later 
from a pulmonary embolism that occurred during an opera-
tion to replace the TPN line. 
The postoperative course of patient 6 was uneventful until 
he developed recurrent Crohn's disease in his native colon 
300 days after transplantation, and then acute rejection of 
the intestinal graft. This patient died of sepsis at 376 days, 10 
days after the graft was removed. Patient 14, who received an 
intestine and colon transplant with a colostomy (Fig. 2C), 
developed clinical signs of graft rejection on postoperative 
day 12, but histopathologic confirmation of the diagnosis and 
initiation of treatment were delayed because an ileal biopsy 
could not be obtained. Biopsies of the transplanted colon 
remained normal until rejection became advanced. By this 
time, respiratory syncitial virus infection precluded augmen-
tation of immunosuppression. The graft was removed at 27 
days, and this child is alive on TPN. 
Rejection. Of the 16 grafts, only one (patient 3) developed 
no evidence of rejection. Thus, the overall incidence of graft 
rejection was 93.8% (15/16). The risk of acute rejection was 
highest at 87.5% (14/16) during the first month and de-
creased to 28.6% (4/14) at 3 months and 36.4% (4/11) at 6 
months, but was still high at 42.9% (317) after 12 months 
(Fig. 5). Moderate-to-severe acute graft rejection was treated 
by OKT3. Patient 1 received two courses of OKT3 for his first 
graft and one for the second. Patients 10, 14, and 15 also 
received a course of OKT3 treatment. Chronic rejection was 
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A 
FIGURE 2. Reconstruction of gastrointestinal continuity and position of enterostomies. (A) Each end of the graft is exteriorized by the 
chimney method. (B) The proximal enterostomy is eliminated and replaced by a tube-jejunostomy. (C) Distal transverse colostomy. (D) 
Bishop-Koop method to exteriorize distal ileum for biopsy monitoring. 
March 1994 TODO ETAL. 845 
A 
III E=- 4 II)E 
SOl 3 
Go c 2 IQ ....... 
0-ftF~ 
if !l 0 +---.....--.---,--............. --,--............. --,-----..--. 
0.5 
0.4 
0.1 
0.0 
o 
~ Oral FK 506 
• I.V. FK 506 
369 
Time After Transplant (months) 
12 
B 
Q) ~k ffF~ oj;' Oog :E:t eO, !IE (f)_ 
3 
III 
Ee 2 II)E 
.!!!"C! CL c 
IQ- 1 0-ftF~ 
~nF 
LI...J 0 
1.0 
0.8 
3l:;: 8 III 0.6 ~ 
IQI:JI 
l~ 1t)"C! 
I~b 0.4 LI. _ 
0.2 
0.0 
0 
-
3 6 
r..a Oral FK 506 
• I.V. FK506 
9 
Time After Transplant (months) 
12 
FIGURE 3. Postoperative immunosuppression for intestinal transplant recipients. Values are expressed as median. (A) Adult patients. (B) 
Pediatric patients. Note striking differences in FK506 doses (greater in children) and prednisone (less in children). 
100 
80 
~ 60 ~ 
iii 
> 
'> 40 
... ---- Patient Survival 
::l 
C/) 
---- Graft Survival 
20 
0 
0 3 6 9 12 15 18 
Time After Intestinal Transplantation (months) 
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seen in two removed grafts (the first graft of patient 1 and 
patient 5). Characteristics of clinical course and angiographic 
and pathological changes have been described elsewhere (5). 
Graft-versus-host disease was not seen in any of these pa-
tients. 
Infection. All except patient 8 experienced more than one 
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FIGURE 5. Incidence and severity of acute rejection after intestinal 
transplantation and at progressively later times postoperatively. 
episode of postoperative bacterial or fungal infection: line 
infection (n=7), abdominal wound (n=5), peritonitis (n=2), 
evidence of translocation (n=2), and others (n=6). 
Cytomegalovirus infection after transplantation was 
strongly influenced by the preoperative serological status 
(Table 2). For example, 7 of the 9 adult patients, who were 
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TABLE 2. CMV Infection after isolated intestinal transplantation 
Donor Recipient (n) Pediatric! CMV Infection 
adult Positive culture Severe infection 
6 4/2 0 0 
+ 1 1/0 1 0 
+ 9 0/9 7 6" 
+ + 0 0/0 0 0 
"Three patients required prolonged hospitalization, and three 
grafts were lost to rejection. 
negative for CMV preoperatively and received grafts from 
CMV-positive donors developed severe clinical disease at 1.5 
to 4 months after transplantation. Three patients required 
frequent hospital readmission for CMV infection treatment. 
Five patients with CMV infection developed graft rejection 
due to reduction of immunosuppression, and 3 of the 5 went 
on to graft removal. One pediatric recipient who was sero-
positive before transplant and received the graft from a se-
ronegative donor (patient 2) had positive culture of CMV in 
urine and sputum, but developed no clinical symptoms. In 
contrast, there were no episodes of CMV infection in the 6 
CMV-seronegative patients who received CMV-seronegative 
intestinal grafts. 
Graft function. Nine of the 11 surviving patients with func-
tioning grafts are free of TPN and on an unrestricted oral 
diet. One patient (patient 7), who was transplanted for 
pseudoobstruction, had a gastrojejunostomy placed surgi-
cally 335 days after transplantation and requires partial nu-
tritional support by TPN because of dysmotility of the stom-
ach. Patient 12 is currently undergoing weaning from 
parenteral to enteral feeding. 
All recipients except for patient 1 gained or maintained 
body weight after 3 months (Fig. 6) and had improved D-
xylose absorption. 
None of the four Crohn's disease patients has developed 
disease recurrence in the transplanted intestine to date. One 
patient (case 4) had recurrence of Crohn's disease to the 
native rectum 12 months after transplantation and was 
medically treated. One patient with desmoid tumor (case 5) 
also has had no recurrence for 14 months. 
DISCUSSION 
Before the introduction of cyclosporine, the longest sur-
vival of an intestinal transplant was 76 days (10) using im-
munosuppressive regimens that included the combination of 
azathioprine and prednisone, to which antilymphocyte globu-
A. Adult B. Pediatric 
160 
140 
l 
§> 120 
6 
~ 100 
~ 
80 
12 15 18 0 6 12 15 18 
Time After Transplant (months) 
FIGURE 6. Body weight changes after intestinal transplantation. (A) 
Adults. (B) Infants and children. 
lin or thoracic duct drainage were added in some cases (1, 11, 
12). After the advent of cyclosporine, isolated intestinal 
grafts were lost to rejection in Toronto (n=l) (13), Chicago 
(n=l) (14), Paris (n=7) (15), Kiel (n=2) (16, 17), London, 
Ontario (n=l) (18), and Uppsala (n=l) (19). However, the 
other 2 recipients, one of an intestinal segment from a living-
related donor (17) and the other of a full small bowel from a 
cadaveric donor (20), are currently alive and maintained to-
tally by an unrestricted oral diet. In our series with FK.506 
immunosuppression, patient and graft survival rates im-
proved to 80% and 68.8%, respectively. Although the fol-
low-up period is still limited, this experience indicates that 
FK.506 has moved isolated intestinal transplantation toward 
clinical practicality. 
Because oftolerogenicity induced by the liver, Grant et al. 
(21) suggested that the intestinal graft be transplanted to-
gether with the liver even in patients who have normal liver 
function. We confine the indication for isolated intestinal 
transplantation only to patients who have irreversible intes-
tinal failure without hepatic abnormalities. However, since it 
is still in the developmental stage, we perform this procedure 
in highly selected patients, such as those whose venous ac-
cesses are running out from major vessel thrombosis or those 
who have a long history of active Crohn's disease that is 
refractory to any conventional treatments. In spite of inten-
sive management by TPN, no microvillus inclusion disease 
patients survived for more than a few years (22), compared 
with our patient (case 2) who is well with an unrestricted oral 
diet for 19 months after transplantation. 
Although isolated intestinal transplantation has thus be-
come feasible under improved immunosuppression this 
achievement has been far from easy. The occurrence of ~evere 
diarrhea and high stomal output have been particularly 
troublesome during the first 3 to 6 months after transplan-
tation, necessitating frequent readmissions for dehydration. 
The cause of diarrhea after intestinal transplantation is mul-
tifactorial, and is enhanced by decreased intestinal transit 
time, increased osmolarity ofluminal contents, increased wa-
ter and electrolyte secretion, bacterial overgrowth, and ste-
atorrhea (23). Intestinal denervation, ischemic damage, in-
terruption of lymphatics, malabsorption, and rejection also 
could be factors of cumulative impact. 
Antidiarrheal medications, such as opiates, loperamide, 
and kaolin-pectin mixture, were not always effective, and in 
5 recent cases an attempt was made to reduce the problem by 
including the ileocecal valve and at least the ascending colon 
in the graft. This approach was mentioned by Lillehei 25 
years ago (24), and has been used in our multivisceral recipi-
ents (4, 25). Although still inconclusive because of the small 
number of patients, small bowel and colon transplant recipi-
ents have tended to have less stomal output and more semi-
formed stool. However, the use of a colostomy instead of a 
distal ileostomy has made passage of the endoscope difficult 
for monitoring by ileal biopsies and was responsible for one 
graft loss in a child whose colon biopsies failed to reflect the 
more proximal acute rejection. In the last patient to receive a 
small and large bowel graft, the distal colostomy was re-
placed with a Bishop-Koop ileostomy (at the suggestion of Dr. 
Adrian Bianchi, Manchester, England). This permitted easy 
access to the ileum and did not increase the amount of stomal 
discharge. 
Several (26-28) but not all (29) experimental studies have 
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suggested the metabolic and/or immunologic advantages of 
draining the venous effluent of the intestinal graft through 
the liver (mesoportal reconstruction) rather than resorting to 
a mesocaval shunt, which may be easier. In the 11 historical 
cases in which information on the operative procedures was 
available (1, 11), portal drainage was used in only two in-
stances, all others having a mesosystemic shunt. We have 
been able to routinely accomplish the more physiologic me-
soportal reconstruction, reserving the mesosystemic shunt 
anastomosis for the eventuality of retransplantation. The 
significance of the method of venous drainage remains unre-
solved. No serious metabolic complications have developed 
from mesocaval shunt in one of our liver-intestine recipients 
at almost 3 years postoperatively (5) or in the long-surviving 
isolated intestinal recipients in studies by Kiel (17) and Paris 
(20). 
CMV has been the most frequent cause of serious infectious 
complications in our patients, with a specific risk for those 
who converted to CMV-positive serology after transplanta-
tion. Six of the 8 developed severe CMV disease, 5 had epi-
sodes of rejection, 3 required prolonged hospitalization, and 3 
underwent graft removal and eventually died. Prophylaxis 
and active therapy were ineffective. In contrast, the patients 
who did not develop CMV infection had a smooth recovery 
and stable postoperative course. Posttransplant disease can 
occur by reactivation of preexisting CMV or by infection from 
blood products-and perhaps most important, by transmis-
sion from infected organs. 
This experience recapitulates that with other kinds of or-
gan transplants. The incidence of CMV pneumonia in sero-
negative recipients after transplantation of the lung from 
seropositive donors was 80%, with mortality exceeding 50% 
(30). When seropositive grafts were given to seropositive re-
cipients, the incidence of CMV pneumonitis decreased to 
20%. After kidney transplantation with prophylaxis with acy-
clovir and hyperimmunoglobulin, CMV disease occurred in 
10% of the seronegative patients receiving CMV-infected or-
gans, while it decreased to 0.8% when CMV-negative grafts 
were given to seronegative patients (31). These same trends, 
but in an exaggerated form, were seen in our transplant 
recipients. These findings suggest the advisability of avoid-
ing transplantation of isolated intestinal grafts from sero-
positive donors to seronegative recipients. However, the 
shortage of otherwise suitable donors and the urgent need of 
some of the recipients requires case-by-case decision making. 
Our experience has addressed the question of whether the 
liver should be transplanted simultaneously with the intes-
tine if recipient liver function is normal in order to exploit the 
so called hepatic tolerogenicity that extends to concomitantly 
transplanted organ(s) from the same donor (32). Although 
this has been a matter for discussion since the first successful 
combined intestine and liver transplantation by Grant et a1. 
(21), our earlier report comparing the evolution of isolated 
intestinal versus composite grafts <containing both liver and 
intestine) showed better results with the intestine alone (4). 
This trend has continued with our subsequent experience. 
Therefore, we perform combined liver and intestinal trans-
plantation only for patients who have failure of both organs. 
Further observations will be required to establish the valid-
ity of this policy, particularly because its application selects 
the sickest patients for the composite procedure and there-
fore biases the results for comparison. 
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